OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Cancer is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Impaired immune responses in blood cancers improved by third COVID-19 vaccine dose	401
Hitting the target in HER2 mutant cancers	275
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	267
TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states	264
Outcompeting neighbors for intestinal cancer initiation	225
MALAT1 protects dormant tumor cells from immune elimination	223
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	214
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells	210
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells	205
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity	202
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	199
Harnessing immune checkpoint trial data in pediatric cancer	195
γδ T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors	186
The never-abating excitement for targeted therapies	179
Targeting network circuitry in glioma	163
Jeffrey W. Pollard (1950–2023)	155
Endothelium directs fat remodeling in cachexia	152
Targeting T cell checkpoints and myeloid suppressor cells is effective in pancreatic cancer	143
CRC malignancy continuum	140
Circumventing the roadblocks to targeting EGFR-driven cancers	135
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma	134
Untangling the threads of immunotherapy research	134
Outcomes of COVID-19 and risk factors in patients with cancer	132
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	127
Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer	127

KDM6B-mediated reprogramming of myeloid cells regulates the response to immunotherapy	118
Gut decisions in CAR T cell therapy	116
PARP11 interfer(on)es with CAR T cell efficacy	116
A low-coverage liquid biopsy for lung cancer	108
The expanding palette of immunotherapy research	104
Diverse routes to melanoma metastasis and ICI resistance	104
Shooting for multiplexed pathology with Orion	103
Enhancing childhood cancer targetability	102
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	101
Alzheimer’s drug turns macrophages against cancer	101
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	100
Master kinases extracted from proteogenomic networks in glioblastoma drive cancer subtypes	91
Proteogenomic analysis of human pancreatic ductal adenocarcinoma	91
Cancer models for reverse and forward translation	90
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma	88
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting	87
Ovarian cancer through a multi-modal lens	86
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	86
An oncolytic circular RNA therapy	85
2-HG modulates glioma macrophages via Trp metabolism	82
Considering molecular alterations as pan-cancer tissue-agnostic targets	82
Improving long-term outcomes in pediatric low-grade glioma	81
An autologous antigen-agnostic dendritic cell therapy that forgoes antigen loading	81
The expanding success of T cell-engaging bispecific antibodies	80
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia	79
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	78
PRMT9 inhibition sparks immune responses in AML	75
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	74
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer	73
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	71
JAK inhibition shows two faces in prostate cancer	70
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	70
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	70
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types	70
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	69
Avoiding CAR-NK cell fratricide	66
Masking T cell engagers mitigates on-target off-tumor activity	65
Enhanced precision in immunotherapy	64
Associations of seven measures of biological age acceleration with frailty and all-cause mortality among adult survivors of childhood cancer in the St. Jude Lifetime Cohort	63
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	63